Study of SON-1010 (IL12-FHAB) in Healthy Adults

Phase 0 Completed 32 enrolled Sonnet BioTherapeutics

RandomizedSequentialDouble-blindTreatment

Summary

SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy adults starting with sentinel participants at each dose level to carefully assess the safety, tolerability, PK, and PD of SON-1010.

Timeline

Start: 2022-07-27
Primary completion: 2023-02-28
Completion: 2023-05-17

Publications

Kenney RT, Cini JK, Dexter S, DaFonseca M, Bingham J, Kuan I, Chawla SP, Polasek TM, Lickliter J, Ryan PJ. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers. Front Immunol. 2024 Feb 29;15:1362775. doi: 10.3389/fimmu.2024.1362775. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SON-1010	Protein / enzyme biologic	—	Subcutaneous

Indications

No indication recorded.